My portfolio
All
Cardiology
Neurology
Oncology
Immunology
Endocrinology
Rheumatology
[product packshot]
Azevra
Chronic heart failure, NYHA Class II–III
Cardiology· Launch Mar 2026
4 visual aids2 reprints
Book detailing[product packshot]
Neurolyx XR
Adjunctive therapy in focal-onset seizures
Neurology· Launch Aug 2025
4 visual aids2 reprints
Book detailing[product packshot]
Ondara
HER2-low metastatic breast cancer
Oncology· Launch Jul 2026
4 visual aids2 reprints
Book detailing[product packshot]
Kelivex
Moderate-to-severe plaque psoriasis
Immunology· Launch Jan 2025
4 visual aids2 reprints
Book detailing[product packshot]
Trivenza
Type 2 diabetes with renal impairment
Endocrinology· Launch Sep 2025
4 visual aids2 reprints
Book detailing[product packshot]
Havestra
Rheumatoid arthritis, biologic-naive
Rheumatology· Launch Q1 2027
4 visual aids2 reprints
Book detailingTop requested resources
Azevra — NYHA II–III Visual Aid
PDF · 12 pages
Neurolyx XR — Focal-onset seizures reprint
PDF · NEJM 2025
Ondara — HER2-low MoA explainer
MP4 · 4:32
Trivenza — Dosing in renal impairment
PDF · 6 pages
Kelivex — Patient case library
Web · 14 cases
Sample inventory
| Product | On hand | 30d out | |
|---|---|---|---|
Azevra 25mg | 64 | 42 | OK |
Azevra 50mg | 12 | 38 | |
Neurolyx XR 100mg | 88 | 21 | OK |
Trivenza 5mg | 6 | 24 | |
Kelivex pen 80mg | 32 | 18 | OK |